27 results
Thumbnail

D2.230 - Cross-Reactivity of Cephalosporins in Patients with IgE-Mediated Allergy to Penicillins: A Systematic Review

Thumbnail

D2.231 - The experiences of ferric carboxymaltose desensitization and provocation

Thumbnail

D2.232 - SDRIFE related to generalized corticosteroids’ hypersensitivity: A case report

Thumbnail

D2.233 - Negative predictive value of skin tests with local anaesthetics

Thumbnail

D2.235 - Is an allergy skin test with local anaesthetics necessary? Real life data with 124 patients

Thumbnail

D2.236 - Drug-induced angioedema by racecadotril in a patient treated with angiotensin-converting enzyme inhibitors

Thumbnail

D2.237 - Corticosteroid allergy, hypertryptasemia and renal transplant

Thumbnail

D2.238 - Successful Prevention of Subsequent L-Asparaginase Hypersensitivity in Children through Premedication: A Single-Center Experience

Thumbnail

D2.239 - The First Successful Desensitization in Abemaciclib Hypersensitivity: A Case Report

Thumbnail

D2.242 - Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a Romanian University Hospital

Thumbnail

D2.243 - From Risk to Solution: Effective Desensitization in a Confirmed Delayed Hypersensitivity Reaction to Albendazole

Thumbnail

D2.245 - Long-Term Outcomes of Beta-Lactam Allergy De-Labelling: A Retrospective 10 year Analysis of Patient Confidence and Antibiotic Tolerance

Thumbnail

D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data

Thumbnail

D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases

Thumbnail

D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin

Thumbnail

D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity

Thumbnail

D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis

Thumbnail

D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes

Thumbnail

D3.416 - Hereditary Alpha-Tryptasemia: A Case Series

Thumbnail

D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"